Chronic Myeloid Leukemia with S348L Mutation: A Case Report
Background: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR-ABL1 fusion gene, which leads to constitutive tyrosine kinase activity. Tyrosine kinase inhibitors (TKIs), such as imatinib, are the first-line therapy and have significantly improved patient outcomes. However, resistance can...